## What is claimed is:

- 1. A method for treating cholinergically induced smooth muscle hyperactivity disorders, comprising the administration to a mammal in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of R,S-*N*-isopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine, R(+)-*N*-isopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine or R(+)-*N*-Isopropyl-3-(2-hydroxy-5-(hydroxymethyl)phenyl)-3-phenylpropylamine or a pharmaceutically acceptable salt thereof.
- 2. The method of claim 1, wherein said compound is R,S-N-isopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine or a pharmaceutically acceptable salt thereof.
- 3. The method of claim 1, wherein said compound is R(+)-N-isopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropyl amine, or a pharmaceutically acceptable salt thereof.
- 4. The method of claim 1, wherein said compound is RS-N-Isopropyl-3-(2-hydroxy-5-(hydroxymethyl)phenyl)-3-phenylpropylamine or a pharmaceutically acceptable salt thereof.
- 5. The method of claim 1, wherein said compound is R(+)-N-Isopropyl-3-(2-hydroxy-5-(hydroxymethyl)phenyl)-3-phenylpropylamine or a pharmaceutically acceptable salt thereof.

6. A method for treating cholinergically induced smooth muscle hyperactivity disorders, comprising the administration to a mammal in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of R,S-N-isopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine, R(+)-N-isopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine, RS-N-Isopropyl-3-(2-hydroxy-5-(hydroxymethyl)phenyl)-3-phenylpropylamine, R(+)-N-Isopropyl-3-(2-hydroxy-5-(hydroxymethyl) phenyl)-3-phenylpropylamine, RS-N,N-diisopropyl-3-(2-hydroxy-5-(hydroxymethyl)phenyl)-3-phenylpropylamine or R(+)-N,N-diisopropyl-3-(2-hydroxy-5-(hydroxymethyl) phenyl)-3-phenylpropylamine or a pharmaceutically acceptable salt thereof, while reducing or eliminating concomitant liability of adverse side effects associated with the corresponding parent compounds, those parent compounds being RS-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine and R(+)-N.N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine.


`

- 7. The method of claim 6, wherein said compound is R,S-N-isopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine or a pharmaceutically acceptable salt thereof.
- 8. The method of claim 6, wherein said compound is R(+)-N-isopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine or a pharmaceutically acceptable salt thereof.

9. The method of claim 6, wherein said compound RS-N-Isopropyl-3-(2-hydroxy-5-(hydroxymethyl)phenyl)-3-phenylpropylamine or a pharmaceutically acceptable salt thereof.

١.

- The method of claim 6, wherein said compound is R(+)-N-Isopropyl-3-(2-hydroxy-5-(hydroxymethyl)phenyl)-3-phenylpropylamine or a pharmaceutically acceptable salt thereof.
- 11. The method of claim 6, wherein said compound is RS-N,N-diisopropyl-3-(2-hydroxy-5-(hydroxymethyl)phenyl)-3-phenylpropylamine or a pharmaceutically acceptable salt thereof.
- 12. The method of claim 6, wherein said compound is R(+)-N,N-diisopropyl-3-(2-hydroxy-5-(hydroxymethyl)phenyl)-3-phenylpropylamine or a pharmaceutically acceptable salt thereof.
- 13. The method of claim 6, wherein said disorders are selected from the group consisting of urinary incontinence and pollakiuria.
- 14. The method of claim 6, wherein said compound or a pharmaceutically acceptable salt thereof is administered in a dose from about 0.5 mg to about 100 mg per day.



- 16. The method of claim 6, wherein said compound or a pharmaceutically acceptable salt thereof is administered orally in the pharmaceutical unit dosage form of a tablet or capsule.
- 17. The pharmaceutical unit dosage form of claim 16. wherein said tablet or capsule is formulated for controlled release upon administration.